Shouwu Miao

This inventor holds 18 USPTO granted patents and 1 published patent application, plus 2 CIPO patents and 8 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Merck Sharp + Dohme Corp., Merck + Co., Inc., Merck Canada Inc.. Active years: 2000-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Shouwu Miao. Retrieved from https://idiyas.com/inventor/shouwu-miao

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 18 (Patent Applications = 1)

% Patents Active = 83.3

CIPO Patents = 2

EPO Patents = 8 (Patent Applications = 7)

Average Co-Inventor Count = 6.7

ph-index = 6

Forward Citations = 125(Granted Patents)

Company Filing History:

11 out of 2,405

Merck Sharp + Dohme Corp.

where one patent can have more than one assignee

Years Active: 2000-2021

Loading Chart...

Areas of Expertise:

GPR120 Agonists

Soluble Guanylate Cyclase

HCV Protease Inhibitors

Immunosuppressants

Spiro Compounds

Azetidine Derivatives

Chemokine Receptor Modulators

Tetracyclic Triterpenes

Potassium Channel Inhibitors

Diazepine Sulfonamides

Triazaspiro Compounds

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11161819 - Substituted tetrahydroisoquinoline compounds useful as GPR120 agonists (2021-11-02),

2. 10428076 - Soluble guanylate cyclase stimulators (2019-10-01),

3. 10030027 - Soluble guanylate cyclase stimulators (2018-07-24),

4. 9365574 - Soluble guanylate cyclase activators (2016-06-14),

5. 8987195 - HCV NS3 protease inhibitors (2015-03-24),

6. 8921555 - Substituted-1,3,8-triazaspiro[4.5]decane-2,4-diones (2014-12-30),

7. 8492398 - Spiroazaindoles (2013-07-23),

8. 8309544 - Spiroindalones (2012-11-13),

9. 8153626 - Substituted diazepine sulfonamides as bombesin receptor subtype-3 modulators (2012-04-10),

10. 7906652 - Heterocycle-substituted 3-alkyl azetidine derivatives (2011-03-15),

11. 7906503 - Substituted 3-alkyl and 3-alkenyl azetidine derivatives (2011-03-15),

12. 7485732 - Substituted 3-alkyl and 3-alkenyl azetidine derivatives (2009-02-03),

13. 6809199 - (Halo-benzo carbonyl)heterocyclo fused phenyl p38 kinase inhibiting agents (2004-10-26),

14. 6632836 - Carbocyclic potassium channel inhibitors (2003-10-14),

15. 6303593 - 3-thienyl and 3-furanyl pyrrolidine modulators of chemokine receptor activity (2001-10-16),

Title: Shouwu Miao: Innovator in Pharmaceutical Compounds

Introduction: Shouwu Miao, located in Edison, NJ, is a prominent inventor with a portfolio of 18 patents. His innovative work primarily focuses on pharmaceutical compounds that have significant implications for treating various metabolic and inflammatory conditions.

Latest Patents: Among his latest patents is the invention of substituted tetrahydroisoquinoline compounds useful as GPR120 agonists. These compounds are represented by a specific formula and are aimed at treating or preventing diabetes, hyperlipidemia, obesity, non-alcoholic steatohepatitis (NASH), inflammation-related disorders, and other related conditions. The inventions also encompass pharmaceutical compositions and methods of treatment utilizing these compounds.

Another significant patent is for soluble guanylate cyclase stimulators, which include compounds that can modulate the body's production of cyclic guanosine monophosphate (cGMP). These compounds are intended for therapy and prophylaxis related to diseases associated with a disturbed cGMP balance. The invention includes pharmaceutical compositions and methods for preparing these drugs for medical use.

Career Highlights: Shouwu Miao has made substantial contributions to pharmaceutical science through his work at major companies such as Merck Sharp & Dohme Corporation and Merck & Company, Inc. His efforts have been instrumental in advancing therapeutic solutions to complex health issues.

Collaborations: Throughout his career, Miao has collaborated with notable professionals in the field, including Kathleen M. Rupprecht and Robert K. Baker. Their combined expertise has fostered innovation and propelled research initiatives aimed at improving health outcomes.

Conclusion: Shouwu Miao’s innovations in pharmaceutical compounds reflect a deep commitment to addressing critical health challenges. His patents not only contribute to scientific knowledge but also offer promising avenues for effective treatments in various diseases.

Profile summary based on public USPTO records.